Charco Neurotech
Founded 2019 · 74 employees on LinkedIn · 9 known investors
Charco Neurotech develops the CUE1, a non-invasive device that uses vibratory stimulation to ease movement symptoms and improve quality of life for people with Parkinson's disease. The company builds its technology together with and for Parkinson's patients based on ongoing scientific research.
Investors · 9
Amadeus Capital PartnersLondon · $50K – $12.7M
Cambridge Angels groupCambridge · $195K – $1.9M
New Wave VenturesLondon
UTECTokyo · $3.1M – $78M
Crista Galli VenturesreportedLondon
Parkwalk AdvisorsreportedLondon
Also in the syndicate · 3
Imperial College Innovation FundMINT Venture PartnersUniversity of Tokyo Edge Capital Partners (UTEC)
Funding
SEC filings, press & company announcements$10M disclosed across 1 round · 2021
- $10MseedNov 2021 · 3 sources
Amadeus Capital Partners (lead), Parkwalk Advisors (lead), Crista Galli Ventures, Imperial College Innovation Fund, MINT Venture Partners, University of Tokyo Edge Capital Partners (UTEC)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Charco Neurotech do?
- Charco Neurotech develops the CUE1, a non-invasive device that uses vibratory stimulation to ease movement symptoms and improve quality of life for people with Parkinson's disease. The company builds its technology together with and for Parkinson's patients based on ongoing scientific research.
- Who are Charco Neurotech's investors?
- Charco Neurotech's investors include Amadeus Capital Partners, Cambridge Angels group, New Wave Ventures, UTEC, Crista Galli Ventures, Parkwalk Advisors.
- How much funding has Charco Neurotech raised?
- Charco Neurotech has disclosed $10M raised across 1 round.